Does Anthem BCBS require prior authorization for 87562?

Anthem BCBS lists 87562 on Virginia Local Precertification/Prior Authorization List (HMO & EPO) for commercial plans, with conditions (list dated September 1, 2026). Verify with the payer before scheduling.

Does Florida Blue require prior authorization for 87562?

Florida Blue lists 87562 on Prior Authorization List: HMO – Marketplace Qualified Health Plans for exchange plans (list dated March 27, 2026). Verify with the payer before scheduling.

What insurance policy changes affect CPT 87562?

There are 3 tracked policy changes affecting CPT 87562, including updates from Blue Cross Blue Shield of Massachusetts, Regence BlueShield, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 87562?

Payers that have issued tracked updates for CPT 87562 include: Blue Cross Blue Shield of Massachusetts, Regence BlueShield, Blue Cross & Blue Shield of Mississippi.

How do I get notified when CPT 87562 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 87562. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for CPT 87562?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

87562 Insurance Policy Changes

CPT 87562 is referenced in 3 tracked payer policy changes from Blue Cross Blue Shield of Massachusetts, Regence BlueShield, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 87562 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross Blue Shield of Massachusetts · Effective Oct 1, 2026Medium impact
Medical Policy Updates for October 2026
Blue Cross Blue Shield of Massachusetts medical policy changes take effect October 1, 2026 across dermatology, hematology and oncology, laboratory, neurology, orthopedics, pharmacy, pulmonology, radiation oncology and urology policies. Prior authorization is required for hematopoietic cell transplantation for autoimmune diseases, now covering multiple sclerosis with criteria, and for radiopharmaceutical codes A9517 and A9530 through Carelon Medical Benefits Management. Carelon genetic testing and sleep program guideline changes take effect November 15, 2026, and Category III CPT codes stay non-covered unless a BCBSMA medical policy describes them as medically necessary.
Regence BlueShield · Effective Oct 1, 2026Medium impact
Identification of Microorganisms Using Nucleic Acid Probes
Medical Policy GT85, Identification of Microorganisms Using Nucleic Acid Probes, is effective October 1, 2026. Nucleic acid testing using a direct or amplified probe technique, with or without quantification, may be considered medically necessary for BK virus, cytomegalovirus, hepatitis B virus, hepatitis C virus, hepatitis D virus, HIV-1, HIV-2, human herpesvirus 6, and influenza virus. Respiratory pathogen panels with 12 or more targets are considered not medically necessary. Testing with quantification or semi-quantification for other microorganisms, hepatitis G virus testing, central nervous system pathogen panels, urinary tract infection pathogen panels, joint infection panels, endometrial pathogen panels, pathogen panels for surgical or chronic wounds, and oral HPV testing are considered investigational. The technique for quantification includes both amplification and direct probes, so simultaneous coding for quantification with either amplification or direct probes is not warranted. SARS-CoV-2 nucleic acid testing is addressed in a separate policy, COVID-19 Testing, Laboratory, Policy No. 74.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Identification of Microorganisms Using Nucleic Acid Probes
Nucleic acid probe testing without quantification of viral load may be considered medically necessary for listed organisms including Bartonella henselae and quintana, Bordetella pertussis, Candida species, Chlamydia, Clostridium difficile, Herpes simplex virus, influenza virus, Mycobacterium tuberculosis, Neisseria gonorrhoeae, Streptococcus group A and group B, Trichomonas vaginalis and Zika virus. Probe testing with or without quantification may be considered medically necessary for cytomegalovirus, hepatitis B and C, HIV-1, HIV-2 and human herpes virus 6, and quantification is investigational for organisms not on that list. Nucleic acid testing with a direct or amplified probe for Gardnerella vaginalis and Hepatitis G is considered investigational, and pathogen panel testing is addressed in the Pathogen Panel Testing medical policy.

Watch 87562

Get one email when a payer policy names 87562, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

See every payer rule for 87562

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 87562 in one place.

See every payer rule

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Medical Policy Updates for October 2026

Identification of Microorganisms Using Nucleic Acid Probes